Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

s Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the timing and scope of clinical studies and trials for nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010). Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the fact that results from pre-clinical studies may not be predictive of results to be obtained in other pre-clinical studies or future clinical trials, delays in commencement and completion of clinical trials, including slower than anticipated patient enrollment and adverse events occurring during the clinical trials, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, the ability to successfully manufacture products in a time-sensitive and cost effective manner, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Avastin(R) (bevacizumab) is a registered trademark of Genentech Inc.

Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Co
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... the Company) (NASDAQ: HOLX ), a leading ... imaging systems and surgical products dedicated to serving the ... (Conceptus) request for an injunction barring future sales of ... and that no royalty will be due to Conceptus ...
... BASIS Science, Inc. ( www.mybasis.com ) the creators of the ... B1 band, will be demoing at the 2012 International CES ... for the first time. The dashboard has been designed as ... health and wellness. "We have designed the Basis ...
Cached Medicine Technology:Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 2Hologic Announces Denial of Conceptus' Request for Injunction in Patent Infringement Suit 3BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... that the latest issue of Inclusive™ magazine, its multimedia publication focused on implant ... edition of the new issue, Volume 6, Issue 2, as well as past ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... All-Star at the annual All-Stars Summit. Google Partners is the platform for search ... receive the full support and tools necessary to run successful search marketing campaigns. ...
(Date:7/30/2015)... ... 30, 2015 , ... Quintessa Medical Spa is happy to offer patients the ... designed specifically for the elimination of excess tissue under the chin, referred to as ... of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Association of ... announcement of the reinstitution of National Prescription Drug Take-Back Days. The 10th event ... AM to 2:00 PM local time. On the 26th, the DEA, with the ...
(Date:7/30/2015)... , ... July 30, 2015 , ... New research finds ... Click here to read more on the Surviving Mesothelioma website. , Researchers ... in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 and 2010. ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2
... A new research finds that the number of individuals with ... double over the next generation//. The results of the study ... Neurology. ,The study highlights the significant challenge facing ... which are ill prepared to meet this impending public health ...
... the government to bring about new and effective campaigns against ... be main reason for this sudden surge in AIDS cases ... there is a phenomenal 41% increase of HIV cases which ... spend $10 million for campaigns which would address these issues ...
... Russia after quarantine measures were lifted August 2006. The incidence ... called for the culling// of 1.5 million birds. ... ,“A laboratory analysis has uncovered the H5N1 bird ... Krasnodar region,” says Aleksei Alekseyenko, an official at the country's ...
... in children may improve their smile but there is no ... study//. The study results were published in the British Journal ... their 20-year long study looked at the impact of braces ... their teeth had little positive impact on their psychological health ...
... in southern Vietnam have plummeted after tests showed that many ... media reported Monday. ,"Today we could only sell ... of a Ho Chi Minh City egg supplier, told the ... as well as prices came after the department of science ...
... used to correct alignment of teeth, do not improve ... later in life, finds a study//. ,Thousands of ... a widespread belief in the dental profession that braces ... of BBC News. ,Bill Shaw and researchers ...
Cached Medicine News:Health News:Worldwide Parkinson's Cases To Double In Next 25 Years 2Health News:Worldwide Parkinson's Cases To Double In Next 25 Years 3
Optical Urethrotome 8667 for telescope 4 mm, 0. For slitting urethral strictures under vision...
OES Pro Optical Urethrotome...
... With a 4.9mm insertion tube, ... and increases maneuverability even through strictured ... wide viewing angle of 125 in ... a large viewing area and simplifying ...
New technology in optics, processing and application. Laser-welded mechanics in stainless steel provide high safety in sterilization. Saphire windows distal and proximal, validated even for autoclavi...
Medicine Products: